MyoStrain's Economic Benefits in the Diagnosis and Management of Heart Failure Detailed in New Health Economics Review
Morrisville, NC, June 19, 2019 – A new article demonstrating the significant cost savings that could be achieved using MyoStrain to detect and manage early heart failure was published in Health Economics Review. The article, authored by Avalon Health Economics (Avalon), compares MyoStrain to Echocardiography (ECHO), the most widely-used diagnostic method for heart function. Avalon developed a cost impact model from both a ‘payer perspective’ and a ‘hospital perspective’ to compare the use of MyoStrain versus Echo to diagnose and manage early-stage heart failure. In the models, MyoStrain showed cost-dominance over Echo from both payer and hospital perspective.
The link to the article is provided below:
Citation: Schneider JE, et al. Economic Evaluation of Cardiac Magnetic Resonance with Fast-SENC in the Diagnosis and Management of Early Heart Failure. Health Economics Review. 2019 May;9(1):13. Doi:10.1186/s13561-019-0229-7.
About Myocardial Solutions, Inc.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain® has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
April 25, 2020